Recall urticaria caused by vedolizumab: case report and literature review.

Some studies have reported the development of moderate and severe de novo SpA-associated disease under vedolizumab (VDZ) treatment for IBD. Herein, we report a case series who developed severe enthesitis under VDZ therapy from a cohort of 90 treated cases. In a single Italian IBD Unit in which 90 cases were on VDZ therapy, we identified 11 cases who developed severe enthesitis. The onset of disease in relationship to VDZ initiation, clinical and sonographic imaging features, and outcomes (including therapy switches) was described. A total of 11 cases, including 8 prior anti-TNF failures, with new-onset entheseal pathology were identified: multifocal (n = 4), unifocal (n = 6), and enthesitis/synovitis/dactylitis (n = 1). The mean duration of symptoms was 46 weeks (range 6-119), the mean CRP was 5.1 mg/dl, and the majority were HLA-B27 negative and showed good clinical response for gut disease. Clinical features and US showed severe enthesitis, including power Doppler change in 7 patients. All patients were initially treated with NSAIDs, and 5 patients underwent local steroid injections. At 12 months, 5/7 cases continued VDZ and 2 were switched to ustekinumab. At 12 months follow-up of 7 cases, 5 patients were in clinical remission and 2 patients had mild enthesitis with minimal increase of power Doppler signal. In addition, 4/7 severe patients developed marked post-inflammatory entheseal calcifications. A predominant isolated severe enthesitis pattern of SpA may develop under VDZ therapy with severe disease in 8% of cases. Most cases continued VDZ therapy.

Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review

Safety of COVID-19 vaccination in patients with clonal mast cell disorders

Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis.

Intravenous Immunoglobulin May Be Beneficial as an Add-on Therapy in DRESS

AB0494 CHARACTERISTICS OF THE PATIENTS WITH POLYARTERITIS NODOSA IN JAPAN

We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma with an incidence of 6 cases per million per year.1 Classic MF in adults can present in different stages, including the patch, plaque, and tumor stages.2 While patients with early patch or plaque stage MF usually have an indolent course, patients developing skin tumors require systemic or radiation therapy due to their aggressive course.3 In addition, several clinico-pathologic variants of MF have been described; eg, poikilodermatous, granulomatous, hypopigmented, folliculotropic, and vesiculobullous variants.

Mosquito Salivary Gland Extracts Induce EBV-Infected NK Cell Oncogenesis Via CD4+ T Cells in Patients with Hypersensitivity to Mosquito Bites

Unusual esophageal injury after atrial fibrillation ablation: Early diagnosis and treatment to optimize outcomes

Current Concepts in the Management of Tuberculosis

Systemic and localized seminal plasma hypersensitivity patients exhibit divergent immunologic characteristics

BackgroundRedback spiders (Latrodectus hasselti) (RBSs) are venomous spiders that have recently spread to Asia from Australia. Since the first case report in 1997 (Osaka), RBS bites have been a clinical and administrative issue in Japan; however, the clinical characteristics and effective treatment of RBS bites, particularly outside Australia remains unclear. This study aimed to elucidate the clinical characteristics of RBS bites and to clarify the effectiveness of the administration of antivenom for treatment.MethodsWe performed a retrospective questionnaire survey from January 2009 to December 2013 to determine the following: patient characteristics, effect of antivenom treatment, and outcomes. To clarify the characteristics of patients who develop systemic symptoms, we compared patients with localized symptoms and those with systemic symptoms. We also examined the efficacy and adverse effects in cases administered antivenom.ResultsOver the 5-year study period, 28 patients were identified from 10 hospitals. Of these, 39.3% were male and the median age was 32 years. Bites most commonly occurred on the hand, followed by the forearm. Over 80% of patients developed local pain and erythema, and 35.7% (10 patients) developed systemic symptoms. Baseline characteristics, vital signs, laboratory data, treatment-related factors, and outcome were not significantly different between the localized and systemic symptoms groups. Six patients with systemic symptoms received antivenom, of whom four experienced symptom relief following antivenom administration. Premedication with an antihistamine or epinephrine to prevent the adverse effects of antivenom was administered in four patients, which resulted in no anaphylaxis. One out of two patients who did not receive premedication developed a mild allergic reaction after antivenom administration that subsided without treatment.ConclusionsApproximately one third of cases developed systemic symptoms, and antivenom was administered effectively and safely in severe cases. Further research is required to identify clinically applicable indications for antivenom use.

Xanthogranulomatous osteomyelitis (XO) is a rare form of chronic osteomyelitis characterized by mass-forming inflammatory lesions rich in lipid-laden macrophages. It commonly presents as an osteolytic, tumor-like bone lesion that may expand rapidly and mimic malignancy on imaging, leading to diagnostic uncertainty. This systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to characterize the clinical presentation, diagnostic strategies, treatment approaches, and outcomes of reported XO cases. Case reports and case series with histopathologic confirmation of XO were included. Extracted data encompassed patient demographics, immune status, anatomic involvement, clinical features, diagnostic modalities, management strategies, and outcomes. A total of 21 patients across 19 studies published between 1984 and 2025 were identified. The tibia (24%), rib (16%), and femur (12%) were the most commonly involved bones. Pain (81%) and swelling or mass formation (52.4%) were the predominant presenting features, while systemic symptoms were less frequent. Histopathologic evaluation established the diagnosis in all cases and was supported by radiographic and magnetic resonance imaging findings. Surgical intervention was performed in 76.2% of cases, whereas antimicrobial therapy was inconsistently administered. Complete clinical resolution was reported in all patients with available follow-up, and no XO-related mortality occurred. XO demonstrates non-specific clinical and radiographic features that often mimic bone malignancy. Surgical management appears to be both diagnostically and therapeutically effective in most reported cases, although standardized antimicrobial treatment strategies remain undefined.

Perianal Crohn's disease in infancy.